DOCSLIB.ORG

Granulocyte Colony-Stimulating Factors for Febrile

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Granulocyte Colony-Stimulating Factors for Febrile Cooper et al. BMC Cancer 2011, 11:404 http://www.biomedcentral.com/1471-2407/11/404 RESEARCHARTICLE Open Access Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis Katy L Cooper1*, Jason Madan2, Sophie Whyte1, Matt D Stevenson1 and Ron L Akehurst1 Abstract Background: Febrile neutropenia (FN) occurs following myelosuppressive chemotherapy and is associated with morbidity, mortality, costs, and chemotherapy reductions and delays. Granulocyte colony-stimulating factors (G- CSFs) stimulate neutrophil production and may reduce FN incidence when given prophylactically following chemotherapy. Methods: A systematic review and meta-analysis assessed the effectiveness of G-CSFs (pegfilgrastim, filgrastim or lenograstim) in reducing FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. G-CSFs were compared with no primary G-CSF prophylaxis and with one another. Nine databases were searched in December 2009. Meta-analysis used a random effects model due to heterogeneity. Results: Twenty studies compared primary G-CSF prophylaxis with no primary G-CSF prophylaxis: five studies of pegfilgrastim; ten of filgrastim; and five of lenograstim. All three G-CSFs significantly reduced FN incidence, with relative risks of 0.30 (95% CI: 0.14 to 0.65) for pegfilgrastim, 0.57 (95% CI: 0.48 to 0.69) for filgrastim, and 0.62 (95% CI: 0.44 to 0.88) for lenograstim. Overall, the relative risk of FN for any primary G-CSF prophylaxis versus no primary G-CSF prophylaxis was 0.51 (95% CI: 0.41 to 0.62). In terms of comparisons between different G-CSFs, five studies compared pegfilgrastim with filgrastim. FN incidence was significantly lower for pegfilgrastim than filgrastim, with a relative risk of 0.66 (95% CI: 0.44 to 0.98). Conclusions: Primary prophylaxis with G-CSFs significantly reduces FN incidence in adults undergoing chemotherapy for solid tumours or lymphoma. Pegfilgrastim reduces FN incidence to a significantly greater extent than filgrastim. Background associated costs and detrimental effects on quality of Neutropenia is the major dose-limiting toxicity of many life [2,3]. In addition, an FN episode has been shown to chemotherapy regimens. Grade 3 and grade 4 neutrope- increase the risk of chemotherapy dose reductions and nia are defined as a neutrophil count < 1.0 × 109/L and delays [4]. Unplanned reductions in chemotherapy dose <0.5×109/L respectively. Febrile neutropenia (FN) is may cause further deaths from cancer in the long-term; defined as neutropenia with fever, usually indicating in a retrospective analysis of breast cancer patients with infection, and is associated with substantial morbidity, a 30-year follow-up, the survival rate was 40% (95% CI: mortality, and costs [1]. The direct risk of mortality 26%, 55%) among patients receiving at least 85% of their associated with FN has been estimated as 9.5% (95% planned dose, but only 21% (95% CI: 14%, 26%) among confidence interval [CI]: 9.2%, 9.8%) in a study of 41,779 patients who received less than 85% [5]. cancer patients hospitalised with FN [1]. Management Recombinant human granulocyte colony-stimulating of FN often requires lengthy hospitalisation, [1] with factors (G-CSFs) stimulate production of mature, func- tionalneutrophils[6].G-CSFshavebeenshownto * Correspondence: [email protected] reduce the incidence of FN when used as prophylaxis 1 School of Health and Related Research (ScHARR), University of Sheffield, following chemotherapy. Three G-CSFs are currently in Sheffield, UK Full list of author information is available at the end of the article common usage: filgrastim, pegfilgrastim, and © 2011 Cooper et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Cooper et al. BMC Cancer 2011, 11:404 Page 2 of 11 http://www.biomedcentral.com/1471-2407/11/404 lenograstim. Filgrastim and lenograstim are administered NHS Economic Evaluation Database (NHS-EED). The as a series of daily injections; clinical studies suggest an Medline search strategy was designed with reference to average of 11 injections per chemotherapy cycle are the previous two reviews, and comprised subject head- required to achieve recovery of the absolute neutrophil ings and text words for G-CSFs combined with a search count (ANC) to within the normal range [7-10]. Pegfil- filter to identify RCTs (Appendix 1). Searches were not grastim is administered as a single injection per che- restricted by language. Bibliographies of retrieved papers motherapy cycle [11,12]. G-CSFs may be administered were searched for any additional relevant studies. as primary prophylaxis (in every chemotherapy cycle from cycle 1) or as secondary prophylaxis (in all remain- Inclusion and exclusion criteria ing cycles following a neutropenic event such as FN or Studies were considered suitable for inclusion if they prolonged severe neutropenia). The overall FN risk is assessed primary G-CSF prophylaxis (pegfilgrastim, fil- dependent on chemotherapy regimen as well as indivi- grastim or lenograstim) administered 1-3 days after the dual patient risk factors such as age, performance status completion of chemotherapy, versus a different G-CSF and disease stage [13]. Guidelines from the European or versus no primary G-CSF prophylaxis. Studies were Organisation for Research and Treatment of Cancer only included if they reported incidence of FN. For con- (EORTC), [13] the American Society of Clinical Oncol- sistency with the two existing systematic reviews, [18,19] ogy (ASCO) [14] and the National Comprehensive Can- only studies of adult cancer patients with solid tumours cer Network (NCCN) [15] recommend that prophylactic or lymphoma were included. Studies allowing concomi- G-CSFs should be used where the risk of FN associated tant antibiotic prophylaxis were included if identical with the chemotherapy regimen is greater than or equal prophylaxis was administered in both study arms. The to 20%, and may be considered where the risk is 10- following study types were excluded: studies of G-CSFs 20%, particularly where additional patient risk factors for treatment of FN; studies in children; studies in are present. patients with leukaemia, myeloid malignancies or myelo- This paper reports a systematic review and meta-ana- dysplastic syndromes; studies of G-CSFs for stem cell lysis of the effect of primary G-CSF prophylaxis (with mobilisation in bone marrow or peripheral blood stem pegfilgrastim, filgrastim or lenograstim) on incidence of cell transplantation; economic analyses; studies with dif- FN. The effect of each G-CSF is assessed in comparison fering drugs, doses or schedules of chemotherapy in with no primary G-CSF prophylaxis and in comparison each arm; studies with differing doses of the same G- with other G-CSFs. CSF in each arm; and studies not published in English. Methods Outcome measures Search strategy The outcome measure assessed in this review was the The systematic review followed the recommendations in incidence of FN over all cycles of chemotherapy within the PRISMA statement [16,17]. A systematic search was each study. FN was chosen as a key clinical outcome undertaken to identify randomised controlled trials due to its direct bearing on morbidity, mortality and (RCTs) of pegfilgrastim, filgrastim or lenograstim, com- hospitalisation rates, and also because this review was pared with no primary G-CSF or with one another, for undertaken alongside the development of an economic the reduction of FN following chemotherapy. A previous model which utilised FN rate as a key parameter. systematic review by Kuderer et al. [18] presented a meta-analysis of FN incidence within RCTs of primary Data extraction G-CSF prophylaxis versus no primary G-CSF prophy- Data was extracted by two reviewers using a form devel- laxis, while a systematic review by Pinto et al. [19] oped for this review and any discrepancies were resolved meta-analysed RCTs of primary prophylaxis using pegfil- through discussion. grastim versus filgrastim. The literature searches within these previous reviews were conducted during 2006. Data synthesis Therefore, databases were searched from 2006 onwards, Meta-analyses were undertaken to compare the effec- whereas studies published prior to 2006 were identified tiveness of G-CSFs versus no prophylaxis and versus from the two existing reviews. Searches were undertaken each other for the reduction of FN. Analyses were in December 2009. The following databases were undertaken using RevMan software (version 5, Cochrane searched: Medline, Medline in Process, EMBASE, Collaboration). Results for each comparison were pre- Science Citation Index, Cochrane Database of Systema- sented as a pooled relative risk and 95% CIs. Although tic Reviews, Cochrane CENTRAL Register of Controlled clinical and statistical heterogeneity existed between stu- Trials, Database of Abstracts of Reviews of Effects dies, there was insufficient data on individual popula- (DARE), Health Technology Assessment Database and tions to facilitate separate analyses. Therefore, for Cooper et al. BMC Cancer 2011, 11:404 Page 3 of 11 http://www.biomedcentral.com/1471-2407/11/404 consistency with existing reviews, all studies were A previous systematic review of prophylactic G-CSF included in the analysis,
Load more

Recommended publications
  • Thymic Peptides and Preparations: an Update
    ¡ Archivum Immunologiae et Therapiae Experimentalis, 1999, 47¢ , 77–82 £ PL ISSN 0004-069X Review Thymic Peptides and Preparations: an Update ¤ O. J. Cordero et al.: Thymic Peptides ¦ ¨ § OSCAR J. CORDERO, A¥ LICIA PIÑEIRO and MONTSERRAT NOGUEIRA Department of Biochemistry and Molecular Biology, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain Abstract. The possibilities of thymic peptides in human therapy are still being described. Here, we focus on their © general characteristics and on recent advances in this area. Key words: thymus; thymic peptides; preclinical investigation; therapeutic use; clinical trials. Thymic peptides, as well as a variety of other purified from porcine and human serum and from calf modulators (IL-1, IL-3, IL-6, GM-CSF) and cell-cell thymus, and named “facteur thymique serique”11. interactions, regulate the process known as thymic se- According to the classical criteria, TH is the unique lection by which pro-thymocytes become mature and peptide that can be recognized as a hormone. Its secre- functional T cells. tion by a subpopulation of thymic epithelial cells (TEC) Several polypeptides have been extracted, mainly is controlled by a pleiotropic mechanism involving its from young calves, and some of them have been suc- own levels and those of prolactine (PRL), growth hor- cessfully isolated and prepared synthetically (Fig. 1). mone (GH) through insulin growth factor 1 (IGF-1) se- The precise role of much of these factors purported to cretion, adrenocorticotropin (ACTH), thyroxin (T4), β- have intrathymic effects is still unknown, although endorphin and β-leukencephalin and IL-1α and β8. many of these compounds exhibit immunobiological Furthermore, reciprocal regulatory actions on the activity.
    [Show full text]
  • Thymopentin and Splenopentin As Immunomodulators Current Stutus
    Immunologic Research 1998;17/3:345-368 Thymopentin and Splenopentin as Immunomodulators Current Stutus 1Department of Immunology, Sanjay Gandhi Post-Graduate Institute of Medical Sciences, Lucknow, India. 2Division of Biopolymers, Central Drug Research Institute, Lucknow, India. 3Department of Microbiology, RML Awadh University, Faizabad, India. Abstract Key Words Splenopentin (SP-5, Arg-Lys-Glu-Val-Tyr) and thymopentin (TP-5, Immunomodulation Arg-Lys-Asp-Val-Tyr) are synthetic immunomodulating peptides Splenin corresponding to the region 32-34 of a splenic product called splenin Splenopentin (SP) and the thymic hormone thymopoietin (TP), respectively. TP Thymopoietin was originally isolated as a 5-kDa (49-amino acids) protein from Thymopentin bovine thymus while studying effects of the thymic extracts on neuro- muscular transmission and was subsequently observed to affect T cell differentiation and function. TP I and II are two closely related polypeptides isolated from bovine thymus. A radioimmunoassay for TP revealed a crossreaction with a product found in spleen and lymph node. This product, named splenin, differs from TP only in position 34, aspartic acid for bovine TP and glutamic acid for bovine splenin and it was called TP III as well. Synthetic pentapeptides (TP-5) and (SP-5), reproduce the biological activities of TP and SP, respectively. It is now evident that various forms of TPs were created by proteolytic cleavage of larger proteins during isolation, cDNA clones have been isolated for three alternatively spliced mRNAs that encodes three distinct human T cell TPs. The immunomodulatory properties of TP, SP, TP-5, SP-5 and some of their synthetic analogs reported in the literature have been briefly reviewed.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Thymopentin Ameliorates Dextran Sulfate Sodium-Induced Colitis by Triggering
    1 Thymopentin ameliorates dextran sulfate sodium-induced colitis by triggering 2 the production of IL-22 in both innate and adaptive lymphocytes 3 Qiuhua Cao1, 2*, Xinghua Gao1, 2*, Yanting Lin1, 2, Chongxiu Yue1, 2, Yue Wang1, 2, Fei 4 Quan1, 2, Zixuan Zhang1, 2, Xiaoxuan Liu1, 2, Yuan Lu1, 2, Yanling Zhan1, 2, Hongbao 5 Yang1, 2, Xianjing Li1, 2, Di Qin5, Lutz Birnbaumer4, Kun Hao3 & Yong Yang1, 2 6 7 1. State Key Laboratory of Natural Medicines, China Pharmaceutical University, 8 Nanjing, Jiangsu 211198, PR China 9 2. Center for New Drug Safety Evaluation and Research, China Pharmaceutical 10 University, Nanjing, Jiangsu 211198, PR China 11 3. Key Lab of Drug Metabolism & Pharmacokinetics, China Pharmaceutical 12 University, Nanjing, Jiangsu 210009, PR China 13 4. Neurobiology Laboratory, National Institute of Environmental Health Sciences, 14 Research Triangle Park, North Carolina 27709, USA, and Institute of Biomedical 15 Research (BIOMED), Catholic University of Argentina, Buenos Aires C1107AFF, 16 Argentina 17 5. School of Sports and Health, Nanjing sport institute, Nanjing, Jiangsu 210001, PR 18 China 19 *These authors contributed equally to this work. 20 Corresponding author: Yong Yang and Kun Hao, China Pharmaceutical University, 21 Nanjing, China. Phone and Fax: 86-025-86185622. E-mail: [email protected] or 22 [email protected]. 1 23 Abstract 24 Background: Ulcerative colitis (UC) is a chronic inflammatory gastrointestinal disease, 25 notoriously challenging to treat. Previous studies have found a positive correlation 26 between thymic atrophy and colitis severity. It was, therefore, worthwhile to investigate 27 the effect of thymopentin (TP5), a synthetic pentapeptide corresponding to the active 28 domain of the thymopoietin, on colitis.
    [Show full text]
  • Aspects of the Usage of Antineoplastic and 1Mmunomodulating Agents in a Section of the Private Health Care Sector
    ASPECTS OF THE USAGE OF ANTINEOPLASTIC AND 1MMUNOMODULATING AGENTS IN A SECTION OF THE PRIVATE HEALTH CARE SECTOR Wilmarie Rheeders B. Pharm Dissertation submitted in Pharmacy Practice, School of Pharmacy at the Faculty of Health Sciences of the North-West University, Potchefstroom, in partial fulfilment of the requirements for the degree Magister Pharmaciae. Supervisor: Prof M.S. Lubbe Co-supervisor: Dr. J.L. Duminy Co-supervisor: Prof. M.P. Stander Potchefstroom November 2008 For all things are from Him, by Him, and for Him. Glory belongs to Him forever! Amen. (Rom. 11:36) ACKNOWLEDGEMENTS To my Lord and Father whom I love, all the Glory! He gave me the strength, insight and endurance to finish this study. 1 also want to express my sincere appreciation to the following people that have contributed to this dissertation: • To Professor M.S. Lubbe, in her capacity as supervisor of this dissertation, my appreciation for her expert supervision, advice and time she invested in this study. • To Dr. J.L Duminy, oncologist and co-supervisor, for all the useful advice, assistance and time he put aside in the interest of this dissertation. • To Professor M.P. Stander, in his capacity as co-supervisor of this study. • To Professor J.H.P. Serfontein, for his guidance, time, effort and advice. • To the Department of Pharmacy Practice as well as the NRF for the technical and financial support. • To Anne-Marie, thank you for your patience, time and continuous effort you put into the data. • To the Pharmacy Benefit Management company for providing the data for this dissertation.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0135901 A1 Moller Et Al
    US 20100135901A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0135901 A1 Moller et al. (43) Pub. Date: Jun. 3, 2010 (54) COMBINATION THERAPY now abandoned, which is a continuation of application No. PCT/DK2004/000683, filed on Oct. 8, 2004. (76) Inventors: Niels Peter Hundahl Moller, (60) Provisional application No. 60/513,422, filed on Oct. Kobenhavn O (DK); Kresten Skak, 22, 2003, provisional application No. 60/569,566, Soborg (DK); Jorn Roland Miller, filed on May 10, 2004. Virum (DK) (30) Foreign Application Priority Data Correspondence Address: WOODCOCKWASHIBURN LLP Oct. 17, 2003 (DK) ............................. PA2OO3O1529 CIRA CENTRE, 12TH FLOOR, 2929 ARCH May 4, 2004 (DK) ............................. PA2004OO707 STREET PHILADELPHIA, PA 19104-2891 (US) Publication Classification (51) Int. Cl. (21) Appl. No.: 12/637,109 A6II 5L/00 (2006.01) A638/20 (2006.01) (22) Filed: Dec. 14, 2009 A6IP35/00 (2006.01) (52) U.S. Cl. ....................................... 424/1.11; 424/85.2 Related U.S. Application Data (57) ABSTRACT (63) Continuation of application No. 12/112,452, filed on Apr. 30, 2008, now abandoned, which is a continuation The invention provides combination treatments with IL-21, of application No. 1 1/404,733, filed on Apr. 14, 2006, analogues and derivatives thereof. US 2010/0135901 A1 Jun. 3, 2010 COMBINATION THERAPY cells have been shown to kill some types of tumor cells via KIR ligand dependent activation. CROSS-REFERENCE TO RELATED PATENT 0007. The immunology involved in cancer disease APPLICATIONS includes a variety of different cells derived from the immune system. Compounds which stimulate Such responses may be 0001.
    [Show full text]
  • Overcoming the Intestinal Barrier a Look Into Targeting Approaches for Improved Oral Drug Delivery Systems
    Journal of Controlled Release 322 (2020) 486–508 Contents lists available at ScienceDirect Journal of Controlled Release journal homepage: www.elsevier.com/locate/jconrel Review article Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems T ⁎ Yining Xu, Neha Shrestha, Véronique Préat, Ana Beloqui Louvain Drug Research Institute, Advanced Drug Delivery and Biomaterials, UCLouvain, Université catholique de Louvain, 1200 Brussels, Belgium ARTICLE INFO ABSTRACT Keywords: Oral drug administration is one of the most preferred and simplest routes among both patients and formulation Oral delivery scientists. Nevertheless, orally delivery of some of the most widely used therapeutic agents (e.g., anticancer Targeting drugs, peptides, proteins and vaccines) is still a major challenge due to the limited oral bioavailability associated Enterocytes with them. The poor oral bioavailability of such drugs is attributed to one or many factors, such as poor aqueous Goblet cells solubility, poor permeability, and enzymatic degradation. Various technological strategies (such as permeation M cells enhancers, prodrugs and nanocarriers) have been developed to enhance the bioavailability of these drugs after L cells ff Transporters oral administration. Among the di erent approaches, advanced and innovative drug delivery systems, especially targeting-based strategies, have garnered tremendous attention. Furthermore, the presence of numerous types of cells and solute carrier transporters throughout the gastrointestinal tract represents numerous potential targeting sites for successful oral delivery that have not yet been exploited for their full potential. This review describes different targeting strategies towards different targeting sites in the gastrointestinal tract. Additionally, exciting improvements in oral drug delivery systems with different targeting strategies (e.g., M cells for oral vaccination and L cells for type 2 diabetes mellitus) are also discussed.
    [Show full text]